跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HULIO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HULIO
Authorized
STANDARD
HULIO
Biosimilar Collaborations Ireland Ltd.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e8e7cf3b5224fd9a
Company
Biosimilar Collaborations Ireland Ltd.
Type
Standard
Approval Details
Approval Id
e8e7cf3b5224fd9a
Drug Approval Canada Name
HULIO
Product Name
HULIO
Status
Marketed
Status Date
2024-06-05
Original Market Date
2022-04-11
Din
02502380
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
90:24.16.92
Atc Original
L04AB04 ADALIMUMAB
Atc Name
l 04 ab 04
Aig Number
0150364003
Company Name
Biosimilar Collaborations Ireland Ltd.
Company Address
UNIT 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Dublin, --, Ireland, D13R20R
Company Detail Path
/organization/biosimilar-collaborations-ireland-ltd
Company Information
Pharmaceutical Company Name
Biosimilar Collaborations Ireland Ltd.
Country Name
Ireland
Active Ingredients
ADALIMUMAB
20 MG / 0.4 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e8e7cf3b5224fd9a
Type
Standard
Back to Health Canada Approvals